Metabolic syndrome and risks of breast cancer outcomes for luminal, triple-negative, and HER2-overexpressing subtypes. Lorona NC, Othus M, Malone KE, Linden HM, et al. Cancer Epidemiol Biomarkers Prev 2024 Nov 1. doi: 10.1158/1055-9965.EPI-24-1167.

Read + Share

Amedeo Smart

Independent Medical Education

Lorona NC, Othus M, Malone KE, Linden HM, et al. Metabolic syndrome and risks of breast cancer outcomes for luminal, triple-negative, and HER2-overexpressing subtypes. Cancer Epidemiol Biomarkers Prev 2024 Nov 1. doi: 10.1158/1055-9965.EPI-24-1167.
PMID: 39485107